drugset
drugset / Trial / NCT05549973

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

NCT05549973 ↗

Phase 1 Unknown 32 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This is a Single-center, Open-label, Single-arm Exploratory Clinical Study to evaluate the safety and efficacy of Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy in relapsed or refractory multiple myeloma patient.

Timeline

Start
2022-09
Primary completion
2023-07
Completion
2024-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule — —
Background Dexamethasone Small molecule — —

Indications

plasma cell myeloma